“Thankful”: Football sensation discovers cancer diagnosis during routine medical examination

Today respiratory diseases have experienced an increase in cases in both children and adults and the respiratory syncytial virus (VRS) is one of the most common. This disease can have mild or severe symptoms, depending on each patient. The United States Food and Drug Administration (FDA) has taken a big step by approving this Wednesday the use of the Pfizer vaccine to treat RSV in older adults.

It is the second RSV vaccine the FDA has approved this month. The pharmaceutical GlaxoSmithKline It also got the green light from the regulator to market its own serum to treat the disease in older adults, The Hill reports.

RSV usually causes mild symptoms in healthy children and adults, but for the elderly it can lead to complications.

Between 60,000 and 160,000 people over the age of 65 are hospitalized each year for the disease in USA. Between 6,000 and 13,000 end up dying, according to The Hill.

In August, Pfizer announced that its vaccine was 85% effective in preventing severe cases of RSV in older adults.

In addition to the vaccine for the elderly, called Abrysvothe FDA is also considering approving Pfizer’s serum for pregnant women, which seeks to prevent RSV cases in babies.